Report on Business Magazine Top 1000 - Company Snapshot

AKELA PHARMA INC.

AKELA PHARMA INC. is an integrated drug development company focused on developing therapies for the inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a Fentanyl formulation delivered using the company's TAIFUN dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD and growth hormone deficiencies.

Address: 11501 Domain Drive, Suite 130 , Austin, TX, USA, 78758
Phone: 512 - 834-0449
Fax: 512 - 834-2105
Web Site:www.akelapharma.com
E-Mail:tbrons@vidacommunication.com
CEO: Greg McKee, C.E.O. & President
CFO: Rudy Emmelot, V.P. Finance
HR : N/A

LATEST ANNUAL FINANCIALS
Date of Balance Sheet: 31-Dec-2010
12 Months, US$
Total Revenue ($000): 13,690
% Change Revenue: -10.9
Profit/Loss ($000): 1,231

GENERAL INFORMATION
Stock Symbol: AKL
Exchanges: TORONTO
Industry: BIOTECHNOLOGY & PHARMACEUTICAL
Company Type: PUBLIC
Company Status: ACTIVE


For more information on this company or any other North America publicly traded stock try globeinvestor.com.

© Copyright 2007 CTVglobemedia Publishing Inc. All Rights Reserved.
Last Updated 01-Dec-2012